MOG and myeloid sarcoma: On day 15 following peptide immunization, when the mean clinical score in each group had reached ∼1–2, mice were treated with purified IgG derived from an MS patient (MS-3) or healthy control (HC) followed by the delivery of Seldegs or controls (MOG-WT26 or PBS vehicle; Figure 5).